PD-L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy

J Eur Acad Dermatol Venereol. 2017 Jul;31(7):e319-e321. doi: 10.1111/jdv.14106. Epub 2017 Jan 31.

Authors

T Steiniche¹, A Vestergaard Danielsen¹, Z Wang², Y Feng³, P Switten Nielsen¹, L Bastholt⁴, H Schmidt⁵, I M Svane⁶, M Dolled-Filhart³, K Emancipator³, R Weiner³, M Busch-Sørensen⁷, W Zhou³

Affiliations

¹ Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark.
² Merck Research Laboratories, MSD China, Beijing, China.
³ Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ, USA.
⁴ Department of Oncology, Odense University Hospital, Odense, Denmark.
⁵ Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
⁶ Department of Oncology, Herlev Hospital, Herlev, Denmark.
⁷ Merck Research Laboratories, MSD Denmark, Copenhagen, Denmark.

PMID: 28045203
DOI: 10.1111/jdv.14106

No abstract available

Publication types

Letter

MeSH terms

B7-H1 Antigen / analysis
B7-H1 Antigen / biosynthesis*
Female
Humans
Immunotherapy
Male
Melanoma / chemistry
Melanoma / metabolism*
Melanoma / mortality*
Melanoma / therapy
Middle Aged
Skin Neoplasms / chemistry
Skin Neoplasms / metabolism*
Skin Neoplasms / mortality*
Skin Neoplasms / therapy
Survival Rate

Substances

B7-H1 Antigen
CD274 protein, human